Biotech Values

[genisi]

FRX/Daxas
First, Forest was smart to propose a narrow label indication, that's how the modest efficacy issue was precluded. Second, there's a need for a treatment other than corticosteroids with their pneumonia risk, that reduces exacerbations in severe COPD patients.Btw, Advair in COPD wasn't approved smoothly, FDA issued an approvable letter after the panel raised questions on efficacy vs SE of steroid especially in older patients.